CytoDyn Submits Breakthrough Therapy Designation A
Post# of 148331
(Total Views: 583)
Posted On: 11/08/2021 6:01:13 AM
CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously
https://www.cytodyn.com/newsroom/press-releas...esignation
https://www.cytodyn.com/newsroom/press-releas...esignation
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼